Skip to main content

Table 5 Monthly costs for antiretroviral drugs by age

From: Estimating age-based antiretroviral therapy costs for HIV-infected children in resource-limited settings based on World Health Organization weight-based dosing recommendations

  Age (years)
Drug product 0.5 1 2 3 4 5 6 7 8 9 10 11 12 13
(Formulation)
ABCA $13.70 $15.26 $19.74 $20.63 $18.57 $15.94 $14.65 $14.70 $15.23 $15.68 $15.89 $15.91 $15.86 $15.82
ABCB $7.54 $8.46 $10.19 $11.13 $12.06 $13.08 $13.89 $14.57 $15.21 $15.68 $15.89 $15.91 $15.86 $15.82
d4T $5.02 $5.08 $2.43 $1.40 $1.23 $1.22 $1.23 $1.25 $1.31 $1.41 $1.54 $1.67 $1.76 $1.81
3TC $2.28 $2.54 $3.28 $3.32 $2.67 $1.88 $1.49 $1.49 $1.68 $1.90 $2.11 $2.27 $2.37 $2.42
EFV NR NR NR $3.39 $4.01 $4.58 $4.93 $5.09 $5.26 $5.49 $5.76 $5.92 $5.86 $5.56
LPV/rA $15.91 $17.85 $21.51 $23.51 $25.45 $27.58 $29.21 $30.32 $30.94 $30.75 $29.78 $28.71 $28.31 $28.86
LPV/rB $15.91 $16.91 $14.11 $13.45 $14.50 $15.93 $16.87 $17.50 $18.41 $19.94 $22.04 $24.37 $26.58 $28.46
NVPA $4.42 $4.97 $5.74 $6.11 $6.39 $6.68 $6.91 $7.00 $6.84 $6.27 $5.33 $4.32 $3.55 $3.16
NVPB $3.77 $4.23 $5.09 $5.57 $6.03 $6.52 $6.87 $7.00 $6.84 $6.27 $5.33 $4.32 $3.55 $3.16
ZDVA $5.02 $5.64 $6.78 $7.25 $7.42 $7.58 $7.78 $8.02 $8.22 $8.23 $8.03 $7.73 $7.47 $7.34
ZDVB $4.19 $4.70 $5.66 $6.19 $6.70 $7.26 $7.69 $8.01 $8.22 $8.23 $8.03 $7.73 $7.47 $7.34
ZDV/3TC $4.19 $4.70 $5.66 $6.19 $6.70 $7.27 $7.72 $8.12 $8.50 $8.82 $9.01 $9.09 $9.12 $9.12
ZDV/3TC/NVP $5.86 $6.58 $7.93 $8.66 $9.38 $10.17 $10.79 $11.29 $11.71 $11.96 $11.96 $11.82 $11.67 $11.58
d4T/3TC $2.51 $2.82 $3.40 $3.71 $4.02 $4.35 $4.61 $4.76 $4.82 $4.70 $4.43 $4.09 $3.83 $3.69
d4T/3TC/NVP $3.35 $3.76 $4.53 $4.95 $5.36 $5.81 $6.17 $6.46 $6.71 $6.86 $6.88 $6.82 $6.74 $6.70
ABC/3TC $7.54 $8.46 $10.19 $11.13 $12.06 $13.08 $13.92 $14.69 $15.51 $16.30 $16.92 $17.34 $17.59 $17.69
  1. Abbreviations: ABC abacavir, d4T stavudine, 3TC lamivudine, EFV efavirenz, LPV/r lopinavir/ritonavir. NVP nevirapine, ZDV zidovudine, NR not recommended.
  2. A. Patients are assumed to start the liquid formulation of the medication and then switch directly to pediatric or adult tablets when recommended (by weight).
  3. B. Patients are assumed to start pediatric tablet formulations of the medication at 0.5 years old (or at earliest recommended age) and then switch to adult tablets when recommended (by weight).